Karyopharm Therapeutics Inc. (NASDAQ:KPTI)’s share price traded down 1.9% during trading on Wednesday . The company traded as low as $6.77 and last traded at $6.85, with a volume of 148,712 shares traded. The stock had previously closed at $6.98.

A number of equities analysts have commented on the stock. Leerink Swann restated a “buy” rating and set a $18.00 price objective on shares of Karyopharm Therapeutics in a research report on Tuesday, May 10th. Canaccord Genuity reaffirmed a “buy” rating and set a $20.00 price target on shares of Karyopharm Therapeutics in a research note on Wednesday, April 6th. Jefferies Group cut shares of Karyopharm Therapeutics from a “buy” rating to a “hold” rating and set a $14.00 price target on the stock. in a research note on Wednesday, June 1st. Zacks Investment Research raised shares of Karyopharm Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, July 21st. Finally, Raymond James Financial Inc. started coverage on shares of Karyopharm Therapeutics in a research note on Friday, May 27th. They set an “outperform” rating and a $13.00 price target on the stock. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and nine have issued a buy rating to the stock. Karyopharm Therapeutics has an average rating of “Buy” and an average target price of $19.50.

The company’s 50 day moving average price is $7.32 and its 200 day moving average price is $7.79. The firm’s market cap is $251.36 million.

Karyopharm Therapeutics (NASDAQ:KPTI) last released its quarterly earnings data on Monday, May 9th. The company reported ($0.75) EPS for the quarter, missing analysts’ consensus estimates of ($0.74) by $0.01. Equities analysts anticipate that Karyopharm Therapeutics Inc. will post ($3.09) earnings per share for the current year.

In other Karyopharm Therapeutics news, major shareholder Ltd Chione sold 10,400 shares of Karyopharm Therapeutics stock in a transaction on Monday, May 16th. The shares were sold at an average price of $8.01, for a total value of $83,304.00. Following the completion of the transaction, the insider now owns 8,967,732 shares of the company’s stock, valued at $71,831,533.32. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.

A hedge fund recently raised its stake in Karyopharm Therapeutics stock. Mutual of America Capital Management LLC raised its position in Karyopharm Therapeutics Inc. (NASDAQ:KPTI) by 60.3% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 88,066 shares of the company’s stock after buying an additional 33,129 shares during the period. Mutual of America Capital Management LLC owned about 0.25% of Karyopharm Therapeutics worth $1,167,000 at the end of the most recent reporting period.

Karyopharm Therapeutics Inc is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. Its segment is the business of discovering, developing and commercializing drugs to treat cancer and certain other major diseases.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.